The DOI matches its Crossref record; 359 of the 359 references it cites were found in a registry or an index.
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
Abstract
ADVERTISEMENT RETURN TO ISSUEPREVReviewNEXTNext Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic AreasYu Zhou†, Jiang Wang†, Zhanni Gu†, Shuni Wang†, Wei Zhu†, José Luis Aceña*‡§, Vadim A. Soloshonok*‡∥, Kunisuke Izawa*⊥, and Hong Liu*†View Author Information† Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China‡ Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU, Paseo Manuel Lardizábal 3, 20018 San Sebastián, Spain§ Department of Organic Chemistry, Autónoma University of Madrid, Cantoblanco, 28049 Madrid, Spain∥ IKERBASQUE, Basque Foundation for Science, María Díaz de Haro 3, 48013 Bilbao, Spain⊥ Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka, Japan 533-0024*E-mail: [email protected]*E-mail: [email protected]*E-mail: [email protected]*E-mail: [email protected]Cite this: Chem. Rev. 2016, 116, 2, 422–518Publication Date (Web):January 12, 2016Publication History Received6 July 2015Published online12 January 2016Published inissue 27 January 2016https://pubs.acs.org/doi/10.1021/acs.chemrev.5b00392https://doi.org/10.1021/acs.chemrev.5b00392review-articleACS PublicationsCopyright © 2016 American Chemical SocietyRequest reuse permissionsArticle Views31495Altmetric-Citations2070LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Chemical structure,Fluorine,Inhibitors,Pharmaceuticals,Reaction products Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–359 of 359
Scherer, K. V., Ono, T., Yamanouchi, K., Fernandez, R. E., Henderson, P. B., & Goldwhite, H. (1985) · Journal of the American Chemical Society · doi:10.1021/ja00289a042 · Cited by 113
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0713-z · Cited by 112
Sofosbuvir: First Global Approval
Keating, G. M., & Vaidya, A. (2014) · Drugs · doi:10.1007/s40265-014-0179-7 · Cited by 112
Belema, M., & Meanwell, N. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500335h · Cited by 112
Xie, C., Wu, L., Han, J., Soloshonok, V. A., & Pan, Y. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500908 · Cited by 112
Self-citationDifluoroethylamines as an amide isostere in inhibitors of cathepsin K
Isabel, É., Mellon, C., Boyd, M. J., Chauret, N., Deschênes, D., Desmarais, S., Falgueyret, J., Gauthier, J. Y., Khougaz, K., Lau, C. K., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.070 · Cited by 111
Zhang, W. (2009) · Green Chemistry · doi:10.1039/b820740b · Cited by 110
Sato, M., Kawakami, H., Motomura, T., Aramaki, H., Matsuda, T., Yamashita, M., Ito, Y., Matsuzaki, Y., Yamataka, K., Ikeda, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900460z · Cited by 109
Ueki, H., Yasumoto, M., & Soloshonok, V. A. (2010) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2010.04.040 · Cited by 108
Self-citationMEK1/2 inhibitors in the treatment of gynecologic malignancies
Miller, C. R., Oliver, K., & Farley, J. H. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.01.008 · Cited by 107
Gan, T. J. (2007) · CNS Drugs · doi:10.2165/00023210-200721100-00003 · Cited by 105
Antifungal therapy in invasive fungal infections
Chen, S. C. ‐., Playford, E. G., & Sorrell, T. C. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.002 · Cited by 103
DeVita, R. J., & Pinto, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4007033 · Cited by 102
Han, J., Nelson, D. J., Sorochinsky, A. E., & Soloshonok, V. A. (2011) · Current Organic Synthesis · doi:10.2174/157017911794697303 · Cited by 101
Self-citationReview of recent advances in nucleophilic C–F bond-forming reactions at sp3 centers
Wu, J. Y.-C. (2014) · Tetrahedron Letters · doi:10.1016/j.tetlet.2014.06.006 · Cited by 100
Sorochinsky, A. E., Katagiri, T., Ono, T., Wzorek, A., Aceña, J. L., & Soloshonok, V. A. (2013) · Chirality · doi:10.1002/chir.22180 · Cited by 99
Self-citationOuellet, S. G., Roy, A., Molinaro, C., Angelaud, R., Marcoux, J.-F., O’Shea, P., & Davies, I. W. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo1018574 · Cited by 99
Soloshonok, V. A., & Berbasov, D. O. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2005.11.004 · Cited by 98
Self-citationSeok, J. I., Lee, D. K., Lee, C. H., Park, M. S., Kim, S., Kim, H., Jo, H., Lee, C. H., & Kim, D. (2009) · Hepatology · doi:10.1002/hep.22959 · Cited by 98
Chemical Dynamic Kinetic Resolution and S/R Interconversion of Unprotected α‐Amino Acids
Takeda, R., Kawamura, A., Kawashima, A., Sato, T., Moriwaki, H., Izawa, K., Akaji, K., Wang, S., Liu, H., Aceña, J. L., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201407944 · Cited by 98
Self-citationSoloshonok, V. A., Ellis, T. K., Ueki, H., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9026055 · Cited by 97
Self-citationRöschenthaler, G., Kukhar, V. P., Kulik, I. B., Belik, M. Y., Sorochinsky, A. E., Rusanov, E. B., & Soloshonok, V. A. (2011) · Tetrahedron Letters · doi:10.1016/j.tetlet.2011.11.096 · Cited by 97
Self-citationOlaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
Gunderson, C. C., & Moore, K. N. (2015) · Future Oncology · doi:10.2217/fon.14.313 · Cited by 97
Kawasuji, T., Johns, B. A., Yoshida, H., Weatherhead, J. G., Akiyama, T., Taishi, T., Taoda, Y., Mikamiyama-Iwata, M., Murai, H., Kiyama, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301550c · Cited by 97
Soloshonok, V. A., Avilov, D. V., & Kukhar, V. P. (1996) · Tetrahedron · doi:10.1016/0040-4020(96)00741-7 · Cited by 96
Self-citationPalmer, J. T., Bryant, C., Wang, D.-X., Davis, D. E., Setti, E. L., Rydzewski, R. M., Venkatraman, S., Tian, Z., Burrill, L. C., Mendonca, R. V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058198r · Cited by 95
Soloshonok, V. A., Hayashi, T., Ishikawa, K., & Nagashima, N. (1994) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)79964-3 · Cited by 94
Self-citationDiscovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template
Hunt, J. T., Mitt, T., Borzilleri, R. M., Gullo-Brown, J. L., Fargnoli, J., Fink, B. E., Han, W.-C., Mortillo, S., Vite, G. D., Wautlet, B. S., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049892u · Cited by 94
Loh, V. M. J., Cockcroft, X. F., Dillon, K. J., Dixon, L., Drzewiecki, J., Eversley, P. J., Gomez, S., Hoare, J., Kerrigan, F., Matthews, I. T. W., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.026 · Cited by 94
Yamada, T., Okada, T., Sakaguchi, K., Ohfune, Y., Ueki, H., & Soloshonok, V. A. (2006) · Organic Letters · doi:10.1021/ol0623668 · Cited by 93
Self-citationOhkura, H., Berbasov, D. O., & Soloshonok, V. A. (2003) · Tetrahedron · doi:10.1016/s0040-4020(03)00138-8 · Cited by 93
Self-citationInagaki, N., Onouchi, H., Maezawa, H., Kuroda, S., & Kaku, K. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70251-7 · Cited by 92
Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
Hoffman-Censits, J. H., & Kelly, W. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2910 · Cited by 92
Trinks, U. P., Buchdunger, E., Furet, P., Kump, W. G., Mett, H., Meyer, T., Mueller, M., Regenass, U., & RIHS, G. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00033a019 · Cited by 91
Bravo, P., Guidetti, M., Viani, F., Zanda, M., Markovsky, A. L., Sorochinsky, A. E., Soloshonok, I. V., & Soloshonok, V. A. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00779-0 · Cited by 90
Self-citationQuinolone 3-Carboxylic Acid Pharmacophore: Design of Second Generation HIV-1 Integrase Inhibitors
Dayam, R., Al‐Mawsawi, L. Q., Zawahir, Z., Witvrouw, M., Debyser, Z., & Neamati, N. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070609b · Cited by 90
Soloshonok, V. A., Sorochinsky, A. E., & Aceña, J. L. (2012) · Synthesis · doi:10.1055/s-0032-1316812 · Cited by 90
Self-citationCockcroft, X. F., Dillon, K. J., Dixon, L., Drzewiecki, J., Kerrigan, F., Loh, V. M. J., Martin, N. M. B., Menear, K. A., & Smith, G. C. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.081 · Cited by 90
Smaill, J. B., Showalter, H. D. H., Zhou, H., Bridges, A. J., McNamara, D. J., Fry, D. W., Nelson, J. M., Sherwood, V., Vincent, P. W., Roberts, B. J., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000372i · Cited by 89
Mechanisms of action of tasquinimod on the tumour microenvironment
Raymond, É., Dalgleish, A. G., Damber, J. ‐., Smith, M. R., & Пили, Р. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2321-8 · Cited by 89
Hoveyda, H. R., Marsault, É., Gagnon, R., Mathieu, A. P., Vézina, M., Landry, A., Wang, Z., Benakli, K., Beaubien, S., Saint‐Louis, C. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007062 · Cited by 88
Identification of a potent and selective non-basic cathepsin K inhibitor
Li, C. S., Deschênes, D., Desmarais, S., Falgueyret, J., Gauthier, J. Y., Kimmel, D. B., Léger, S., Massé, F., McGrath, M. E., McKay, D. J., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.12.071 · Cited by 88
Isaacs, J. T., Пили, Р., Qian, D. Z., Dalrymple, S. L., Garrison, J. B., Kyprianou, N., Björk, A., OLSSON, A. G., & Leanderson, T. (2006) · The Prostate · doi:10.1002/pros.20509 · Cited by 88
Lepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01355-13 · Cited by 88
Novel therapeutic strategies targeting HIV integrase
Quashie, P. K., Sloan, R. D., & Wainberg, M. A. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-34 · Cited by 85
Diamant, Z., Sidharta, P. N., Singh, D., O'Connor, B. J., Zuiker, R. G. J. A., Leaker, B. R., Silkey, M., & Dingemanse, J. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12357 · Cited by 85
Kmentová, I., Sutherland, H. S., Palmer, B. D., Blaser, A., Franzblau, S. G., Wan, B., Wang, Y., Ma, Z., Denny, W. A., & Thompson, A. M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101288t · Cited by 85
Mimura, H., Kawada, K., Yamashita, T., Sakamoto, T., & Kikugawa, Y. (2010) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.12.023 · Cited by 83
Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions
Papachristou, D. J., Basdra, E. K., & Papavassiliou, A. G. (2010) · Medicinal Research Reviews · doi:10.1002/med.20224 · Cited by 81
Wong, H. H., Vernillet, L., Peterson, A., Ware, J. A., Lee, L., Martini, J., Yu, P., Li, C., Rosario, G. D., Choo, E. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0445 · Cited by 81
Review of teriflunomide and its potential in the treatment of multiple sclerosis
Kieseier, B. C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4474 · Cited by 79
Pettipher, R., & Whittaker, M. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2013997 · Cited by 77
Katagiri, T., Yoda, C., Furuhashi, K., Ueki, K., & Kubota, T. (1996) · Chemistry Letters · doi:10.1246/cl.1996.115 · Cited by 76
Tedizolid (TR-701): a new oxazolidinone with enhanced potency
Kanafani, Z. A., & Corey, G. R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.660250 · Cited by 73
Shi, Z.-C., Devasagayaraj, A., Gu, K., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800338j · Cited by 72
Kim, J., Wu, D., Hwang, D., Miller, D. D., & Dalton, J. T. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.088344 · Cited by 72
Potential therapeutic targets for neurokinin-1 receptor antagonists
Duffy, R. A. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.9 · Cited by 72
Biftu, T., Scapin, G., Singh, S. B., Feng, D., Becker, J. W., Eiermann, G. J., He, H., Lyons, K., Patel, S. B., Petrov, A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.095 · Cited by 71
Kim, S.-H., Menon, H., Jootar, S., Saikia, T., Kwak, J., Sohn, S. K., Park, J. S., Jeong, S. H., Kim, H., Kim, Y.-K., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.096776 · Cited by 71
Schwartz, S. L., Akinlade, B., Klasen, S., Kowalski, D. L., Zhang, W., & Wilpshaar, W. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0012 · Cited by 70
Smith, C. J., Ali, A., Hammond, M. L., Li, H., Lu, Z., Napolitano, J. B., Taylor, G. E., Thompson, C. F., Anderson, M. S., Chen, Y., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200484c · Cited by 70
Mei, H., Xie, C., Aceña, J. L., Soloshonok, V. A., Röschenthaler, G., & Han, J. (2015) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201500787 · Cited by 69
Self-citationTachykinin receptor antagonists in clinical trials
Quartara, L., Altamura, M., Evangelista, S., & Maggi, C. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903379530 · Cited by 67
He, Y., Yin, D., Perera, M. A., Kirkovsky, L. I., Stourman, N. V., Li, W., Dalton, J. T., & Miller, D. D. (2002) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(02)01335-1 · Cited by 67
Diastereoselective Reductive Amination of Aryl Trifluoromethyl Ketones and α‐Amino Esters
Hughes, G., Devine, P. N., Naber, J. R., O'Shea, P. D., Foster, B. S., McKay, D. J., & Volante, R. P. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200603745 · Cited by 66
Straub, A. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00034-2 · Cited by 65
A Novel Approach to the Synthesis of Symmetric Optically Active 2,5-Dioxopiperazines
Basiuk, V. A., Gromovoy, T. Y., Chuiko, A. A., Soloshonok, V. A., & Kukhar, V. P. (1992) · Synthesis · doi:10.1055/s-1992-26131 · Cited by 65
Self-citationYasumoto, M., Ueki, H., Ono, T., Katagiri, T., & Soloshonok, V. A. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.11.026 · Cited by 64
Self-citationSuzuki, Y., Han, J., Kitagawa, O., Aceña, J. L., Klika, K. D., & Soloshonok, V. A. (2014) · RSC Advances · doi:10.1039/c4ra13928c · Cited by 63
Self-citationIdentification of JTP‐70902, a p15INK4b‐inductive compound, as a novel MEK1/2 inhibitor
Yamaguchi, T., Yoshida, T., Kurachi, R., Kakegawa, J., Hori, Y., Nanayama, T., Hayakawa, K., Abe, H., Takagi, K., Matsuzaki, Y., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00604.x · Cited by 63
Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis
Saliu, O. Y., Crismale, C., Schwander, S., & Wallis, R. S. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm291 · Cited by 63
Cai, A., Zheng, D., Qiu, R., Mai, W., & Zhou, Y. (2013) · Disease Markers · doi:10.1155/2013/432136 · Cited by 63
Self-citationLivermore, J., & Hope, W. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.683859 · Cited by 62
Non-Peptide Gonadotropin-Releasing Hormone Receptor Antagonists
Betz, S. F., Zhu, Y., Chen, C., & Struthers, R. S. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701249f · Cited by 61
Self-disproportionation of enantiomers of 3,3,3-trifluorolactic acid amides via sublimation
Yasumoto, M., Ueki, H., & Soloshonok, V. A. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.10.002 · Cited by 61
Self-citationKawasuji, T., Johns, B. A., Yoshida, H., Taishi, T., Taoda, Y., Murai, H., Kiyama, R., Fuji, M., Yoshinaga, T., Seki, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3010459 · Cited by 61
Omarigliptin: First Global Approval
Burness, C. B. (2015) · Drugs · doi:10.1007/s40265-015-0493-8 · Cited by 59
Trametinib (GSK1120212) in the treatment of melanoma
Salama, A. K. S., & Kim, K. B. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.770475 · Cited by 59
Inagaki, N., Onouchi, H., Sano, H., Funao, N., Kuroda, S., & Kaku, K. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70149-9 · Cited by 59
Chemical approach for interconversion of (S)- and (R)-α-amino acids
Sorochinsky, A. E., Ueki, H., Aceña, J. L., Ellis, T. K., Moriwaki, H., Sato, T., & Soloshonok, V. A. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40541a · Cited by 58
Self-citationDalrymple, S. L., Becker, R. E., & Isaacs, J. T. (2007) · The Prostate · doi:10.1002/pros.20573 · Cited by 58
Thompson, A. M., Murray, D. K., Elliott, W. L., Fry, D. W., Nelson, J. A., Showalter, H. D. H., Roberts, B. J., Vincent, P. W., & Denny, W. A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970366v · Cited by 57
Clevudine myopathy in patients with chronic hepatitis B
Kim, B. K., Oh, J., Kwon, S. Y., Choe, W. H., Ko, S. Y., Rhee, K. H., Seo, T. H., Lim, S. D., & Lee, C. H. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.019 · Cited by 57
Idelalisib—targeting PI3Kδ in patients with B-cell malignancies
Burger, J. A., & Okkenhaug, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.42 · Cited by 56
Jennbacken, K., Welén, K., OLSSON, A. G., Axelsson, B., Törngren, M., Damber, J., & Leanderson, T. (2011) · The Prostate · doi:10.1002/pros.21495 · Cited by 55
Veltkamp, S. A., Kadokura, T., Krauwinkel, W. J. J., & Smulders, R. A. (2011) · Clinical Drug Investigation · doi:10.1007/bf03256922 · Cited by 55
New first and second generation inhibitors of human immunodeficiency virus-1 integrase
Pendri, A., Meanwell, N. A., Peese, K. M., & Walker, M. A. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.586631 · Cited by 55
Isavuconazonium: First Global Approval
McCormack, P. L. (2015) · Drugs · doi:10.1007/s40265-015-0398-6 · Cited by 54
Tucci, F. C., Zhu, Y., Struthers, R. S., Guo, Z., Gross, T. D., Rowbottom, M. W., Acevedo, O. L., Gao, Y., Saunders, J., Xie, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049218c · Cited by 54
Henschke, J. P., Lin, C., Wu, P., Tsao, W.-S., Liao, J., & Chiang, P. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b00601 · Cited by 51
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases
Seyedmousavi, S., Verweij, P. E., & Mouton, J. W. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.990382 · Cited by 50
Huang, W., Zhu, X., Wang, Y., Azam, M., Wen, D. J., Sundaramoorthi, R., Thomas, R. M., Liu, S., Banda, G., Lentini, S. P., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900166t · Cited by 49
A Practical Synthesis of L-FMAU from L-Arabinose
Du, J., Choi, Y., Lee, K., Chun, B. K., Hong, J. H., & Chu, C. K. (1999) · Nucleosides and Nucleotides · doi:10.1080/15257779908043066 · Cited by 48
Xie, C., Wu, L., Mei, H., Soloshonok, V. A., Han, J., & Pan, Y. (2014) · Tetrahedron Letters · doi:10.1016/j.tetlet.2014.09.001 · Cited by 48
Self-citationIsaacs, J. T. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.514262 · Cited by 47
Synthesis of Fluorinated β-Amino Acids
Sorochinsky, A. E., Mikami, K., Fustero, S., Sánchez‐Roselló, M., Aceña, J. L., & Soloshonok, V. A. (2011) · Synthesis · doi:10.1055/s-0030-1260173 · Cited by 47
Self-citationSelf-disproportionation of enantiomers of α-trifluoromethyl lactic acid amides via sublimation
Yasumoto, M., Ueki, H., & Soloshonok, V. A. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.11.010 · Cited by 45
Self-citationFraser, G. L., Hoveyda, H. R., & Tannenbaum, G. S. (2008) · Endocrinology · doi:10.1210/en.2008-0804 · Cited by 45
Maeno, M., Tokunaga, E., Yamamoto, T., Suzuki, T., Ogino, Y., Ito, E., Shiro, M., Asahi, T., & Shibata, N. (2014) · Chemical Science · doi:10.1039/c4sc03047h · Cited by 45
The preclinical development of regorafenib for the treatment of colorectal cancer
Miura, K., Satoh, M., Kinouchi, M., Yamamoto, K., Hasegawa, Y., Philchenkov, A. A., Kakugawa, Y., & Fujiya, T. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.924923 · Cited by 43
Fretz, H., Valdenaire, A., Pothier, J., Hilpert, K., Gnerre, C., Peter, O., Leroy, X., & Riederer, M. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400122f · Cited by 43
Norman, P. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.839658 · Cited by 42
Jones, S. A., Murakami, E., Delaney, W. E., Furman, P. A., & Hu, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00599-13 · Cited by 42
Blackie, J. A., Bloomer, J. C., Brown, M. J. B., Cheng, H., Elliott, R. L., Hammond, B., Hickey, D. M. B., Ife, R. J., Leach, C. A., Lewis, V. A., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00473-0 · Cited by 41
Small‐Molecule Therapeutics for Ebola Virus (EBOV) Disease Treatment
Izawa, K., Aceña, J. L., Wang, J., Soloshonok, V. A., & Liu, H. (2015) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201501158 · Cited by 39
Self-citationAceña, J. L., Sorochinsky, A. E., Katagiri, T., & Soloshonok, V. A. (2012) · Chemical Communications · doi:10.1039/c2cc37491a · Cited by 39
Self-citationWielert-Badt, S., Lin, J., Lorenz, M., Fritz, S., & Kinne, R. K.-H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9905460 · Cited by 38
Jin, H., Cianchetta, G., Devasagayaraj, A., Gu, K., Marinelli, B. S., Samala, L., Scott, S., Stouch, T. R., Tunoori, A. R., Wang, Y., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.005 · Cited by 38
Wzorek, A., Klika, K. D., Drabowicz, J., Sato, A., Aceña, J. L., & Soloshonok, V. A. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00831f · Cited by 38
Self-citationMantlo, N. B., & Escribano, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400574e · Cited by 37
Wang, J., Liu, H., Aceña, J. L., Houck, D., Takeda, R., Moriwaki, H., Sato, T., & Soloshonok, V. A. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40594j · Cited by 37
Self-citationOgawa, S., Nishimine, T., Tokunaga, E., Nakamura, S., & Shibata, N. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.12.002 · Cited by 37
Berbasov, D. O., Ojemaye, I. D., & Soloshonok, V. A. (2004) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2003.11.032 · Cited by 37
Self-citationModeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors
Gao, Y., Feng, D., Sheridan, R. P., Scapin, G., Patel, S. B., Wu, J. K., Zhang, X., SinhaRoy, R., Thornberry, N. A., Weber, A. E., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.106 · Cited by 35
Chancellor, D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3585 · Cited by 35
Kumar, S., Tan, E. Y., Hartmann, G., Biddle, Z., Bergman, A. J., Dru, J., Ho, J. Z., Jones, A. N., Staskiewicz, S. J., Braun, M. P., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028704 · Cited by 35
Oguro, Y., Miyamoto, N., Takagi, T., Okada, K., Awazu, Y., Miki, H., Hori, A., Kamiyama, K., & Imamura, S. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.042 · Cited by 34
MEK Inhibition in the Treatment of Advanced Melanoma
Salama, A. K. S., & Kim, K. B. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0336-2 · Cited by 33
Guinea, J., & Bouza, E. (2008) · Future Microbiology · doi:10.2217/17460913.3.6.603 · Cited by 32
Inagaki, N., Kondo, K., Yoshinari, T., Ishii, M., Sakai, M., Kuki, H., & Furihata, K. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0226-x · Cited by 31
Tan, E. Y., Hartmann, G., Chen, Q., Pereira, A., Bradley, S. A., Doss, G. A., Zhang, A. S., Ho, J. Z., Braun, M. P., Dean, D. C., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028696 · Cited by 31
Fox, B. M., Sugimoto, K., Iio, K., Yoshida, A., Zhang, J., Li, K., Hao, X., Labelle, M., Smith, M.-L., Rubenstein, S. M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500135c · Cited by 31
Deeks, S. G., Kar, S., Gubernick, S. I., & Kirkpatrick, P. N. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2512 · Cited by 31
Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist
Ohno, Y., Okano, M., Imaki, J., Tatara, A., Okumura, T., & Shimizu, S. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.04.027 · Cited by 30
Li, C., Zhang, W., Zhou, F.-Y., Chen, C., Zhou, L., Li, Y.-F., Liu, L., Pei, F., Luo, H., Hu, Z.-X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077049 · Cited by 30
Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk
Tall, A. R. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.006 · Cited by 30
Xie, C., Mei, H., Wu, L., Han, J., Soloshonok, V. A., & Pan, Y. (2014) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2014.06.015 · Cited by 30
Self-citationPangallo, B. A., Dellva, M. A., D’Souza, D. N., Essink, B., Russell, J. D., & Goldberger, C. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.03.014 · Cited by 29
Fluorination by Sulfur Tetrafluoride
Wang, C. J. (1985) · Organic reactions · doi:10.1002/0471264180.or034.02 · Cited by 29
Qing, F., Liu, Y., Yang, Y., et al. (2014) · Synlett · doi:10.1055/s-0034-1379600 · Cited by 28
Boyd, H., Fell, S. C. M., Flynn, S. T., Hickey, D. M. B., Ife, R. J., Leach, C. A., Macphee, C. H., Milliner, K. J., Moores, K., Pinto, I. L., et al. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00510-2 · Cited by 28
Serrano‐Wu, M. H., Coppola, G. M., Gong, Y., Neubert, A. D., Chatelain, R. E., Clairmont, K. B., Commerford, R., Cosker, T., Daniels, T., Hou, Y. M., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3000512 · Cited by 28
Henschke, J. P., Wu, P., Lin, C., Chen, S., Chiang, P., & HSIAO, C. ‐. (2015) · The Journal of Organic Chemistry · doi:10.1021/jo502839e · Cited by 28
Vorapaxar: A Review of Its Use in the Long-Term Secondary Prevention of Atherothrombotic Events
Frampton, J. E. (2015) · Drugs · doi:10.1007/s40265-015-0387-9 · Cited by 27
Convenient synthesis of fluoroalkyl α- and β-aminophosphonates
Röschenthaler, G., Kukhar, V. P., Kulik, I. B., Sorochinsky, A. E., & Soloshonok, V. A. (2011) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2011.05.005 · Cited by 26
Self-citationNew Therapeutics to Treat Castrate‐Resistant Prostate Cancer
Acar, Ö., Esen, T., & Lack, N. A. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/379641 · Cited by 26
Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold
Schwehm, C., Li, J., Song, H., Hu, X., Kellam, B., & Stocks, M. J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500503n · Cited by 26
Navari, R. M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s76158 · Cited by 25
Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors
Pinard, E., Alberati, D., Borroni, E., Fischer, H., Hainzl, D., Jolidon, S., Moreau, J., Narquizian, R., Nettekoven, M. H., Norcross, R. D., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.086 · Cited by 24
Antiplatelet therapy: Controversial aspects
COCCHERI, S. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.10.036 · Cited by 23
SGLT Inhibitors: a Novel Target for Diabetes
Kanwal, A., & Banerjee, S. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.78 · Cited by 22
Discontinued drugs in 2012: endocrine and metabolic
Colca, J. R. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.829038 · Cited by 21
A review of tasquinimod in the treatment of advanced prostate cancer
Heer, R., Williamson, S. C., & Hartley, A. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s31500 · Cited by 21
Duveau, D. Y., Hu, X., Walsh, M. J., Shukla, S., Skoumbourdis, A. P., Boxer, M. B., Ambudkar, S. V., Shen, M., & Thomas, C. J. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.111 · Cited by 21
Bui, Q. T., & Wilensky, R. L. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903501513 · Cited by 21
Kielbasa, W., Quinlan, T., Jin, L., Xu, W., Lachno, D. R., Dean, R. A., & Allen, A. J. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0151 · Cited by 18
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
Khan, M., Saif, A., Sandler, S. A., & Mirrakhimov, A. E. (2014) · ISRN Oncology · doi:10.1155/2014/931858 · Cited by 18
Prospects for MEK inhibitors for treating cancer
Martín-Liberal, J., Lagares‐Tena, L., & Larkin, J. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.892578 · Cited by 18
Zhang, X.-D., Yan, J., Yan, G., Sun, X.-Y., Ji, J., Li, Y., Hu, Y., & Wang, H. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.104 · Cited by 17
Design of a novel class of biphenyl CETP inhibitors
Lu, Z., Napolitano, J. B., Theberge, A. B., Ali, A., Hammond, M. L., Tan, E., Tong, X., Xu, S. S., Latham, M. J., Peterson, L. B., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.019 · Cited by 16
Newly approved integrase inhibitors for clinical treatment of AIDS
Gu, W.-G. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.09.013 · Cited by 15
Ball, S. G., Dellva, M. A., D’Souza, D. N., Marangell, L. B., Russell, J. M., & Goldberger, C. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.006 · Cited by 15
Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein.
Thompson, C. F., Ali, A., Quraishi, N. Q., Lu, Z., Hammond, M., Sinclair, P., Anderson, M., Eveland, S., Guo, Q., Hyland, S. A., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100309n · Cited by 15
Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial
Nadal, R., Taplin, M., & Joaquim Bellmunt, B. (2014) · Future Oncology · doi:10.2217/fon.13.275 · Cited by 14
Frederick, M. O., Frank, S. A., Vicenzi, J. T., LeTourneau, M. E., Berglund, K. D., Edward, A. W., & Alt, C. A. (2014) · Organic Process Research & Development · doi:10.1021/op500025v · Cited by 14
The year's new drugs and biologics, 2014: Part I
Graul, A., Cruces, E., & Stringer, M. (2015) · Drugs of today · doi:10.1358/dot.2015.51.1.2279964 · Cited by 14
SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors
Lu, Z., Chen, Y., Napolitano, J. B., Taylor, G. E., Ali, A., Hammond, M. L., Deng, Q., Tan, E., Tong, X., Xu, S. S., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.039 · Cited by 11
Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management
Katz, P. M., & Leiter, L. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.017 · Cited by 6
Markowitz, J. S., & Brinda, B. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.939955 · Cited by 2
Cited by
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,655
Electrochemical strategies for C–H functionalization and C–N bond formation
Kärkäs, M. D. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00619e · Cited by 1,003
Kaiser, D., Klose, I., Oost, R., Neuhaus, J., & Maulide, N. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00111 · Cited by 887
Buglioni, L., Raymenants, F., Slattery, A., Zondag, S. D. A., & Noël, T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00332 · Cited by 781
The unique fluorine effects in organic reactions: recent facts and insights into fluoroalkylations
Ni, C., & Hu, J. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00351f · Cited by 737
Metadata
- Authors
- Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-01-12
- Volume
- 116
- Issue
- 2
- Pages
- 422-518
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2237872262
- Cited by
- 2,808
- References
- 359
- FWCI
- 16.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.